Long-term follow-up and patterns of response, progression, and hyperprogression in patients after PD-1 blockade in advanced sarcoma Journal Article
| Authors: | Klemen, N. D.; Hwang, S.; Bradic, M.; Rosenbaum, E.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; Movva, S.; Thornton, K. A.; Chi, P.; Nacev, B. A.; Chan, J. E.; Bartlett, E. K.; Richards, A. L.; Singer, S.; Donoghue, M. T. A.; Tap, W. D.; D'Angelo, S. P. |
| Article Title: | Long-term follow-up and patterns of response, progression, and hyperprogression in patients after PD-1 blockade in advanced sarcoma |
| Abstract: | Purpose: Programmed cell death protein 1 (PD-1) blockade can mediate objective responses in advanced sarcomas, but their durability has not been established and it is unclear if hyperprogressive disease (HPD) occurs in sarcomas treated with PD-1 inhibitors. Experimental Design: We pooled patients who were treated prospectively with nivolumab or pembrolizumab as monotherapy or with bempegaldesleukin, epacadostat, ipilimumab, or talimogene laherparepvec. We did a new independent assessment for HPD and analyzed clinical, pathologic, and genomic data from baseline tumor biopsies. Our primary endpoint was the incidence of HPD; secondary endpoints were clinical or genomic correlates of response or HPD. Results: We treated 134 patients with advanced sarcoma from 2015 to 2019. Twenty-one patients (16%) had a complete or partial response (CR/PR), and 30% of responses were durable for over 2 years. Forty-eight (36%) patients had stable disease (SD), 45 (34%) had progressive disease withoutHPD (PD), and 15 (11%) had HPD. Five patients (4%) were not evaluable for HPD. The sarcoma subtypes, sites of metastasis, clinical course, and genomic alterations in patients withPDandHPDwere similar, exceptHPDtumors were smaller at baseline. Conclusions: In patients with advanced sarcoma, PD-1 blockade can mediate durable responses. HPD occurs in sarcoma at an incidence that is similar to what has been reported in other solid tumors, but patients with HPD were clinically and biologically similar to those who had PD. Further research is required to establish whether HPD is a biologically distinct phenomenon and whether a theoretical risk of HPD should influence patient management. © 2021 The Authors. |
| Journal Title: | Clinical Cancer Research |
| Volume: | 28 |
| Issue: | 5 |
| ISSN: | 1078-0432 |
| Publisher: | American Association for Cancer Research |
| Date Published: | 2022-03-01 |
| Start Page: | 939 |
| End Page: | 947 |
| Language: | English |
| DOI: | 10.1158/1078-0432.Ccr-21-3445 |
| PUBMED: | 34965948 |
| PROVIDER: | scopus |
| PMCID: | PMC8898277 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 1 April 2022 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
Related MSK Work